Table 1.
Baseline Characteristics of Patients With Pancreatic Adenocarcinoma With Diabetes
| Characteristic | Metformin Use | Total (N = 980) | P | |
|---|---|---|---|---|
| Ever (n = 366) | Never (n = 614) | |||
| Age, years | .18 | |||
| Mean (SD) | 66.8 (10.2) | 67.7 (10.6) | 67.4 (10.4) | |
| Median | 68.0 | 68.0 | 68.0 | |
| Q1, Q3 | 60.0, 74.0 | 60.0, 76.0 | 60.0, 75.0 | |
| Range | 37.0-92.0 | 29.0-93.0 | 29.0-93.0 | |
| Gender, No. (%) | .09 | |||
| Male | 227 (62.0) | 347 (56.5) | 574 (58.6) | |
| Female | 139 (38.0) | 267 (43.5) | 406 (41.4) | |
| Race, No. (%) | .10 | |||
| White | 338 (94.4) | 569 (96.6) | 907 (95.8) | |
| Non-White | 20 (5.6) | 20 (3.4) | 40 (4.2) | |
| Missing | 8 | 25 | 33 | |
| Usual BMI | .007 | |||
| No. | 325 | 539 | 864 | |
| Mean (SD) | 31.4 (6.2) | 30.3 (6.2) | 30.7 (6.2) | |
| Median | 30.4 | 29.3 | 29.7 | |
| Q1, Q3 | 27.0, 34.7 | 26.2, 33.5 | 26.5, 34.2 | |
| Range | 19.7-59.0 | 16.9-62.2 | 16.9-62.2 | |
| Duration of diabetes, years | < .001 | |||
| > 2 (long-standing DM) | 203 (55.5%) | 197 (32.1%) | 400 (40.8%) | |
| 0-2 (new-onset DM) | 163 (44.5%) | 417 (67.9%) | 580 (59.2%) | |
| Maximum tumor dimension, cm* | .90 | |||
| No. | 93 | 174 | 267 | |
| Mean (SD) | 3.8 (1.4) | 3.8 (1.5) | 3.8 (1.5) | |
| Median | 3.5 | 3.7 | 3.7 | |
| Q1, Q3 | 3.0, 4.5 | 2.8, 4.5 | 2.8, 4.5 | |
| Range | 0.0-8.4 | 0.3-9.0 | 0.0-9.0 | |
| Stage of disease, No. (%) | .30 | |||
| Resected | 97 (26.5) | 187 (30.5) | 284 (29.0) | |
| Locally Advanced | 132 (36.1) | 222 (36.2) | 354 (36.2) | |
| Metastatic | 137 (37.4) | 204 (33.3) | 341 (34.8) | |
| Missing | 0 | 1 | 1 | |
Abbreviations: BMI, body mass index; DM, diabetes mellitus; SD, standard deviation, Q1, 25th percentile; Q3, 75th percentile.
*
Maximum tumor dimension measure is primarily available in patients with resected stage.